Xencor, Inc. (XNCR)

Market Cap	896.20M +7.6%
Revenue (ttm)	125.58M +13.7%
Net Income	-91.92M
EPS	-1.24
Shares Out	73.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	103,386
Open	12.61
Previous Close	12.53
Day's Range	12.19 - 12.61
52-Week Range	6.92 - 18.69
Beta	0.99
Analysts	Buy
Price Target	22.33 (+82.73%)
Earnings Date	May 6, 2026

About XNCR

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 3, 2013
• Employees: 260
• Stock Exchange: NASDAQ
• Ticker Symbol: XNCR
• Website: https://www.xencor.com

Financial Performance

In 2025, Xencor's revenue was $125.58 million, an increase of 13.65% compared to the previous year's $110.49 million. Losses were -$91.92 million, -60.48% less than in 2024.

Analyst Summary

According to 10 analysts, the average rating for XNCR stock is "Buy." The 12-month stock price target is $22.33, which is an increase of 82.73% from the latest price.

Price Target

$22.33

(82.73% upside)

Analyst Consensus: Buy